- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01084668
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs (QUALITY)
25 czerwca 2012 zaktualizowane przez: Abbott
A Post-marketing Observational Study of the Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic DMARDs Over a Period of 1 Year (QUALITY)
The aim of this post-marketing observational study (PMOS) was to obtain further data on long-term safety, efficacy, and quality of life outcomes for adalimumab in routine clinical use in participants with moderate to severe chronic plaque psoriasis after unsustainable clinical response to other biologic disease modifying anti-rheumatic drugs (BDMARDs).
There are few data so far showing the effects of switching from other BDMARDs to adalimumab in patients with moderate to severe chronic plaque psoriasis.
This study was designed to evaluate the long-term effectiveness of adalimumab in participants with moderate to severe chronic plaque psoriasis using the Psoriasis Area and Severity Index (PASI) in participants previously treated with efalizumab, infliximab, or etanercept and who either never achieved satisfactory response, achieved satisfactory response initially but lost it over time, or discontinued treatment due to intolerance/side effect(s) or other reasons, for example after regular stop of etanercept.
Przegląd badań
Status
Zakończony
Warunki
Szczegółowy opis
This was a non-interventional PMOS conducted in a prospective, single-country, multicenter format to assess the quality of life of psoriasis patients taking adalimumab as prescribed by their physician in accordance with the terms of the local marketing authorization with regard to dose, population, and indication.
The prescription of adalimumab was clearly separated from the decision to include the participant in this study.
No procedures other than standard of care were to have been performed.
Visits were non-interventional and timing of participant appointments was left to each physician.
After therapy initiation, visits occurred over 12 months usually close to Weeks 4, 12, 24, 36, and 52 for a total of 6 visits (Visits 1 through 6 including Screening).
Because participant visits were left to the physician, participant failure to meet the suggested visit weeks did not constitute a breach of the protocol.
Typ studiów
Obserwacyjny
Zapisy (Rzeczywisty)
46
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Feldkirch, Austria, 6807
- Site Reference ID/Investigator# 27435
-
Graz, Austria, 8010
- Site Reference ID/Investigator# 27436
-
Graz, Austria, 8036
- Site Reference ID/Investigator# 38445
-
Linz, Austria, 4020
- Site Reference ID/Investigator# 27443
-
Vienna, Austria, 1030
- Site Reference ID/Investigator# 27442
-
Vienna, Austria, 1130
- Site Reference ID/Investigator# 27440
-
Vienna, Austria, 1160
- Site Reference ID/Investigator# 27437
-
Vienna, Austria, A-1090
- Site Reference ID/Investigator# 27439
-
Wels, Austria, 4600
- Site Reference ID/Investigator# 23309
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Metoda próbkowania
Próbka bez prawdopodobieństwa
Badana populacja
Hospital, Dermatology
Opis
Inclusion Criteria:
- Patients for whom adalimumab therapy is indicated and has been prescribed according to the product label
- Patients aged 18 years and older
- Unsatisfactory response to prior BDMARDS (efalizumab, infliximab, etanercept) in patients with moderate to severe chronic plaque psoriasis or achievement of satisfactory response initially, but loss over time or discontinuation of treatment due to intolerance/side effects(s) or other reasons e.g. restart after regular stop of etanercept
- Patients must fulfill Austrian Treatment Recommendations for use of BDMARD in psoriasis (chest X-ray and purified protein derivative [PPD] skin test negative for tuberculosis)
- Patient is willing to consent to data being collected and provided to Abbott
- Patient must be able and willing to self-administer Pen injections or have a qualified person available to administer Pen injections
Exclusion Criteria:
- Patients who meet contraindications as outlined in the latest version of the Humira-Pen Summary of Product Characteristics (SPC)
- Patients who do not meet the criteria for the use of BDMARDs of the Austrian Treatment Recommendations
- Patients participating in another study or clinical trial
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
---|
Adalimumab
Participants with moderate to severe chronic plaque psoriasis treated with adalimumab after biologic disease modifying anti-rheumatic drug (BDMARD) failure
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Psoriasis Area and Severity Index (PASI) Score
Ramy czasowe: Inclusion visit (Week 0), Week 4, Week 36, Week 52
|
Psoriasis Area and Severity Index (PASI) score is based on assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and area affected as observed on the day of examination.
The score ranges from 0 (best outcome) to 72 (worst outcome).
|
Inclusion visit (Week 0), Week 4, Week 36, Week 52
|
Reduction in Psoriasis Area and Severity Index Score of at Least 75% (PASI75)
Ramy czasowe: Inclusion visit (Week 0) to Week 52
|
PASI75 is the number of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 52 (final visit).
PASI score is based on assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and area affected as observed on the day of examination.
The score ranges from 0 (best outcome) to 72 (worst outcome).
|
Inclusion visit (Week 0) to Week 52
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Dermatology Life Quality Index (DLQI) Score
Ramy czasowe: Inclusion visit (Week 0), Week 4, Week 36, Week 52
|
Dermatology Life Quality Index (DLQI) Score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week.
Responses to each are: very much, a lot, a little, or not at all.
The DLQI score ranges from 0 (best) to 30 (worst).
|
Inclusion visit (Week 0), Week 4, Week 36, Week 52
|
Nail Psoriasis Severity Index (NAPSI) Score
Ramy czasowe: Inclusion visit (Week 0), Week 4, Week 36, and Week 52
|
The nails are graded for nail matrix psoriasis and nail bed psoriasis.
The sum of these two scores is the total score for that nail.
Per nail, the NAPSI score ranges from 0 (no nail psoriasis) to 4 (most severe nail psoriasis).
|
Inclusion visit (Week 0), Week 4, Week 36, and Week 52
|
Tolerability and Safety Assessed by Collection and Classification of Adverse Reactions
Ramy czasowe: From the time of participant consent until 70 days after last dose of study drug
|
Tolerability and safety were assessed by collecting adverse events during the course of the study up to 70 days following the last dose of physician-prescribed adalimumab.
The number of participants experiencing a serious or non-serious adverse event is summarized.
See the Reported Adverse Event section for details.
|
From the time of participant consent until 70 days after last dose of study drug
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Współpracownicy
Śledczy
- Dyrektor Studium: Astrid Dworan-Timler, MD, Abbott Austria
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 listopada 2008
Zakończenie podstawowe (Rzeczywisty)
1 kwietnia 2011
Ukończenie studiów (Rzeczywisty)
1 kwietnia 2011
Daty rejestracji na studia
Pierwszy przesłany
28 lutego 2010
Pierwszy przesłany, który spełnia kryteria kontroli jakości
9 marca 2010
Pierwszy wysłany (Oszacować)
10 marca 2010
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
29 czerwca 2012
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
25 czerwca 2012
Ostatnia weryfikacja
1 czerwca 2012
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- P10-708
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .